<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:07:18 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>
      Fourth Quarter and Full Year 2019 Financial Results | BridgeBio
    </title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio. Learn more today!"
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Fourth Quarter and Full Year 2019 Financial Results | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio. Learn more today!"
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2020-03-02T13:29:14+00:00"
    />
    <meta
      property="article:modified_time"
      content="2022-06-23T15:13:59+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Julianne Twining" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Julianne Twining" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="10 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/",
            "name": "Fourth Quarter and Full Year 2019 Financial Results | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2020-03-02T13:29:14+00:00",
            "dateModified": "2022-06-23T15:13:59+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/f567122d9069e4cac0b57561cb43f962"
            },
            "description": "BridgeBio today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio. Learn more today!",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/f567122d9069e4cac0b57561cb43f962",
            "name": "Julianne Twining",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g",
              "caption": "Julianne Twining"
            },
            "url": "https://bridgebio.com/author/julianne/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/style1746.css?ver=1734502320"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-css1746.css?ver=1734502320"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrust1746.css?ver=1734502320"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scripts1746.js?ver=1734502320"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modal1746.js?ver=1734502320"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/1991.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../indexe741.html?p=1991" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed5a95.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embed2c6a?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-portfolio-progress%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-1991 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma Reports Fourth Quarter and Full Year 2019
              Financial Results and Highlights Portfolio Progress
            </h1>
            <section>
              <p>
                <em
                  >-Achieved multiple clinical and pre-clinical milestones
                  across BridgeBio’s pipeline<br /><br />-Delivered pipeline
                  expansion with addition of five new drug development and
                  discovery programs; BridgeBio’s portfolio now includes more
                  than 20 potential medicines<br /><br />-Ended quarter with
                  $577.1 million in cash, cash equivalents and marketable
                  securities</em
                >
              </p>

              <p>
                SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) &#8212; BridgeBio
                Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical
                company focused on genetic diseases, today is reporting its
                fourth quarter and full year 2019 financial results and recent
                progress across its portfolio, which now includes more than 20
                drug development and discovery programs.
              </p>

              <p>
                2019 was a year of significant growth and milestone achievements
                for BridgeBio. The company initiated its first New Drug
                Application (NDA) with the United States Food and Drug
                Administration (FDA) and added five new drug development and
                discovery programs to its pipeline, which target diseases in
                endocrinology, ophthalmology, otology, neurology and
                musculoskeletal therapeutic areas. Veteran biotech and
                pharmaceutical industry leaders joined BridgeBio’s board of
                directors and the company as senior leaders, including the
                recent board appointment of Ronald J. Daniels, president of
                Johns Hopkins University. The company went public on June 27,
                2019 and raised approximately $401 million in gross proceeds in
                its initial public offering.
              </p>

              <p>
                “BridgeBio was founded nearly five years ago on the back of two
                big ideas: that there had to be a better way to finance critical
                biomedical research and that there was a tremendous amount of
                medical innovation that was trapped, without a way to move into
                the clinic where it could help patients,” said BridgeBio founder
                and CEO Neil Kumar, Ph.D. “Today BridgeBio has more than 20 drug
                development and discovery programs in our pipeline. We initiated
                our first new drug application with the FDA and we are on track
                to file our second later this year, along with the anticipated
                filing of multiple investigational new drug applications. We are
                demonstrating that our model is working and has the potential to
                produce an array of life-changing therapies for people in need.”
              </p>

              <p>
                <strong
                  ><u>Pipeline growth:<br /></u><br />We recently disclosed five
                  new genetic medicine product candidates in the
                  pipeline:</strong
                >
              </p>

              <ul class="wp-block-list">
                <li>
                  <strong>Encaleret</strong> – Calcium sensing receptor
                  antagonist for autosomal dominant hypocalcemia type 1 (ADH1):
                  IND application for the treatment of ADH1 became effective in
                  late 2019; Phase 2 ready.
                </li>
                <li>
                  <strong>Zuretinol</strong> –Synthetic retinoid for inherited
                  retinal disease due to RPE65 or LRAT gene mutations: Phase 2/3
                  study initiating in 2020.
                </li>
                <li>
                  <strong>BBP-418</strong> – Substrate supplementation therapy
                  for limb-girdle muscular dystrophy type 2i (LGMD2i).
                </li>
                <li>
                  <strong>BBP-472</strong> – Brain-permeable inhibitor of
                  PI3KBfor children with autism-spectrum disorders (ASD)
                  characterized by loss of the PTEN protein. This program is in
                  preclinical development.
                </li>
                <li>
                  <strong>BBP-815</strong> –AAV gene therapy for nonsyndromic
                  hearing loss caused by recessive mutations in the TMC1 gene.
                  This program is undergoing early proof of concept animal
                  studies.
                </li>
              </ul>

              <p>
                <strong
                  ><u>Fourth quarter 2019 and recent pipeline progress:<br /></u
                  ><br />Mendelian</strong
                >
              </p>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Low-dose infigratinib – FGFR1-3 inhibitor for
                    achondroplasia: </strong
                  >Initiated clinical program consisting of an observational
                  study (PROPEL, <a
                    href="https://clinicaltrials.gov/ct2/show/NCT04035811"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT04035811</a
                  >) and Phase 2 dose-ranging study (PROPEL2, <a
                    href="https://clinicaltrials.gov/ct2/show/NCT04265651"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT04265651</a
                  >) in children with achondroplasia, the most common form of
                  genetic short stature. 
                </li>
                <li>
                  <strong
                    >Fosdenopterin – cPMP replacement therapy for MoCD type
                    A: </strong
                  >Initiated a rolling submission of an NDA with the United
                  States FDA for the treatment of patients with molybdenum
                  cofactor deficiency (MoCD) type A.
                </li>
                <li>
                  <strong
                    >Topical patidegib gel for Gorlin syndrome and
                    high-frequency basal cell carcinoma</strong
                  ><sup>1</sup><strong>: </strong>Completed enrollment of
                  pivotal Phase 3 clinical trial in patients with Gorlin
                  Syndrome (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT03703310"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT03703310</a
                  >) and initiated Phase 2 study in high-frequency basal cell
                  carcinoma (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04155190"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT04155190</a
                  >). 
                </li>
                <li>
                  <strong>BBP-265 (AG10) – TTR stabilizer for ATTR:</strong
                  > Presented positive <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/43957e77-b297-4bea-ae24-99b027f6e890"
                    target="_blank"
                    rel="noreferrer noopener"
                    >data</a
                  > from Phase 2 Open Label Extension (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT03536767"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT03536767</a
                  >) in transthyretin amyloid cardiomyopathy at the American
                  Heart Association’s 2019 Scientific Sessions.
                </li>
              </ul>

              <p>
                ___________<br /><sup>1</sup> PellePharm, which is focused on
                developing patidegib topical gel, 2% entered into a strategic
                collaboration with LEO Pharma in November 2018, which includes
                an option for LEO Pharma to acquire PellePharm.<br /><br />
              </p>

              <p><strong>Targeted Oncology</strong></p>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Infigratinib – FGFR1-3 inhibitor for FGFR+ cancer:</strong
                  > Received FDA Fast Track Designation in adults with
                  first-line advanced or metastatic cholangiocarcinoma and
                  Orphan Drug Designation for the treatment of
                  cholangiocarcinoma, and initiated Phase 3 study in advanced 1L
                  cholangiocarcinoma as a first-line therapy  (<a
                    href="https://www.qedprooftrial.com/"
                    target="_blank"
                    rel="noreferrer noopener"
                    >PROOF trial</a
                  >, <a
                    href="https://clinicaltrials.gov/ct2/show/NCT03773302"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT03773302</a
                  >).
                </li>
                <li>
                  <strong
                    >BBP-398 – SHP2 inhibitor for treatment-resistant
                    cancer:</strong
                  > Presented data (<a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/319f8cef-74f0-416d-9b96-27ed44bec74d"
                    target="_blank"
                    rel="noreferrer noopener"
                    >link to poster</a
                  >) highlighting the discovery and preclinical activity of our
                  potent and selective SHP2 inhibitor potentially both as
                  monotherapy and in combination with approved agents.
                </li>
              </ul>

              <p><strong>Gene Therapy</strong></p>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-812 – Gene therapy candidate for Canavan
                    disease:</strong
                  > Opened a natural history study in Canavan disease (<a
                    href="https://treatcanavan.com/"
                    target="_blank"
                    rel="noreferrer noopener"
                    >treatcanavan.com</a
                  >) and presented preclinical data (<a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/9ed10908-3c1a-4d45-bb2e-6b4c2e32afe9"
                    target="_blank"
                    rel="noreferrer noopener"
                    >link to poster</a
                  >) demonstrating intravenous (IV) dosing of BridgeBio’s
                  experimental therapy for Canavan disease (BBP-812) achieved
                  broad central nervous system delivery.
                </li>
                <li>
                  <strong>BBP-631 – Gene therapy candidate for CAH:</strong
                  > Presented preclinical update (<a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/523d7b03-2996-4462-9b27-d058f02bccbd"
                    target="_blank"
                    rel="noreferrer noopener"
                    >link to poster</a
                  >) for gene therapy candidate BBP-631 in congenital adrenal
                  hyperplasia (CAH) due to 21-hydroxylase deficiency wherein IV
                  dosing of non-human primates with BBP-631 resulted in durable
                  delivery and expression of the gene product to the adrenal
                  tissue.
                </li>
              </ul>

              <p>
                <strong><u>Upcoming milestones:</u></strong>
              </p>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Anticipate disclosing additional new product candidates and
                    filing multiple new INDs in 2020.</strong
                  >
                </li>
                <li>
                  <strong
                    >BBP-589 – COL7A protein replacement therapy for recessive
                    dystrophic epidermolysis bullosa:</strong
                  > Plan to share topline data from the ongoing Phase 1/2 study
                  (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT03752905"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT03752905</a
                  >) in 2020.
                </li>
                <li>
                  <strong>Low-dose infigratinib</strong> – <strong
                    >FGFR1-3 inhibitor for achondroplasia: </strong
                  >Anticipate dosing of first child in Phase 2 dose-ranging
                  study (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04265651"
                    target="_blank"
                    rel="noreferrer noopener"
                    >PROPEL2</a
                  >) in the coming months.
                </li>
                <li>
                  <strong>BBP-265 (AG10) – TTR stabilizer for ATTR:</strong> On
                  track to complete enrollment in the Phase 3 study of AG10 in
                  ATTR-CM in 2H20 (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT03860935"
                    target="_blank"
                    rel="noreferrer noopener"
                    >ATTRibute-CM</a
                  >). A Phase 3 study of AG10 in ATTR-PN (ATTRibute-PN) is on
                  track to begin in 1H20.
                </li>
                <li>
                  <strong>Encaleret</strong> –<strong
                    > Calcium sensing receptor antagonist for autosomal dominant
                    hypocalcemia type 1 (ADH1):</strong
                  > Phase 2b ready. 
                </li>
                <li>
                  <strong
                    >Infigratinib – FGFR1-3 inhibitor for FGFR+ cancer:</strong
                  > Plan to present updated results at a major oncology meeting
                  in 2020. Remain on track to submit new drug application for
                  FDA approval in cholangiocarcinoma in 2020. Plan to dose first
                  patients in a Phase 3 study in FGFR3+ adjuvant urothelial
                  carcinoma (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04197986"
                    target="_blank"
                    rel="noreferrer noopener"
                    >NCT04197986</a
                  >) and a Phase 2 tumor-agnostic study in patients with fusions
                  or activating mutations in the FGFR1, 2 or 3 genes in 2020.
                </li>
              </ul>

              <p>
                <strong><u>Organizational Growth:</u></strong>
              </p>

              <ul class="wp-block-list">
                <li>
                  <strong>Ronald J. Daniels, board member: </strong>President of
                  Johns Hopkins University joined board of directors.
                </li>
                <li>
                  <strong
                    >Jennifer Cook, board member and senior advisor: </strong
                  >Genentech veteran who led Roche Pharma’s European commercial
                  business joined board of directors and serves as a special
                  advisor to BridgeBio.
                </li>
                <li>
                  <strong
                    >Eli Wallace, chief scientific officer in residence for
                    oncology: </strong
                  >Medicinal chemist and strategic executive leader who oversaw
                  entire research organizations at companies such as Peloton
                  Therapeutics and Array BioPharma joined BridgeBio to lead
                  oncology research.
                </li>
              </ul>

              <p>
                <strong
                  ><u
                    >Fourth quarter and full-year 2019 financial results:</u
                  ></strong
                >
              </p>

              <p>
                <strong
                  >Cash, Cash Equivalents and Marketable Securities</strong
                >
              </p>

              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, totaled $577.1 million as of December 31, 2019
                compared with $436.1 million at December 31, 2018.
              </p>

              <p><strong>License revenue</strong></p>

              <p>
                License revenue for the fourth quarter of 2019 was $13.8 million
                and for the full year 2019 was $40.6 million. The full year 2019
                revenue was comprised mainly of the upfront payment recognized
                by our subsidiary company, Eidos Therapeutics, Inc. upon
                execution of its License Agreement with Alexion Pharmaceuticals,
                Inc.
              </p>

              <p><strong>Operating Expenses</strong></p>

              <p>
                Operating expenses for the fourth quarter of 2019 were $92.5
                million, as compared to $65.6 million for the same period in the
                prior year. The increase in operating expenses of $26.9 million
                was primarily attributable to increase in headcount and
                external-related costs to support the growth of our operations.
              </p>

              <p>
                Full year 2019 operating expenses were $306.8 million, as
                compared to $183.7 million for the full year in 2018. The
                increase of $123.1 million was mainly due to the increase in
                external-related costs to support the progression in our
                research and development programs and growth of our operations
                as well as increase in headcount.
              </p>

              <p><strong>Other Income (Expense), Net</strong></p>

              <p>
                Other income (expense), net for the fourth quarter of 2019 was
                ($5.5) million, as compared to $16.3 million for the same period
                in 2018. The change of $21.8 million was primarily attributable
                to a gain of $19.3 million that we recognized on deconsolidation
                of our controlled variable interest entity, PellePharm, Inc. in
                2018.
              </p>

              <p>
                Other income (expense), net for the full year 2019 was ($22.3)
                million, as compared to $14.2 million for the full year in 2018.
                The change of $36.5 million was primarily attributable to an
                increase in our net loss of equity method investments by $20.9
                million in 2019 and the gain of $19.3 million on deconsolidation
                of our controlled variable interest entities, PellePharm, Inc.
              </p>

              <p class="has-text-align-center">
                <strong>BRIDGEBIO PHARMA, INC.</strong><br /><strong
                  >Condensed Consolidated Statements of Operations</strong
                ><br /><em
                  >(in thousands, except shares and per share amounts)</em
                >
              </p>

              <div class="wp-block-image">
                <figure class="aligncenter">
                  <img
                    fetchpriority="high"
                    decoding="async"
                    width="769"
                    height="556"
                    class="wp-image-1977"
                    src="../../wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.41-PM.png"
                    alt=""
                    srcset="
                      https://bridgebio.com/wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.41-PM.png         769w,
                      https://bridgebio.com/wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.41-PM-300x217.png 300w,
                      https://bridgebio.com/wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.41-PM-768x555.png 768w
                    "
                    sizes="(max-width: 769px) 100vw, 769px"
                  />
                </figure>
              </div>

              <p class="has-text-align-center">
                <br /><strong>BRIDGEBIO PHARMA, INC.</strong><br /><strong
                  >Condensed Consolidated Balance Sheets</strong
                ><br /><em>(In thousands)</em>
              </p>

              <div class="wp-block-image">
                <figure class="aligncenter size-full">
                  <img
                    decoding="async"
                    width="605"
                    height="400"
                    class="wp-image-1978"
                    src="../../wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.38-PM.png"
                    alt=""
                    srcset="
                      https://bridgebio.com/wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.38-PM.png         605w,
                      https://bridgebio.com/wp-content/uploads/2020/03/Screen-Shot-2020-03-01-at-7.46.38-PM-300x198.png 300w
                    "
                    sizes="(max-width: 605px) 100vw, 605px"
                  />
                </figure>
              </div>

              <p>
                (1)     Upon the closing of our IPO on July 1, 2019, we
                completed a reorganization (the “Reorganization”), whereby all
                unitholders of BridgeBio Pharma LLC, our predecessor entity
                (“BBP LLC”) exchanged their units for shares of common stock of
                BridgeBio Pharma, Inc. (the “Corporation”), and BBP LLC became a
                wholly-owned subsidiary of the Corporation. Subsequent to the
                Reorganization, as the sole managing member, BridgeBio operates
                and controls all of BBP LLC’s businesses and affairs. The
                condensed consolidated financial statements as of and for the
                year ended December 31, 2018 are derived from the audited
                consolidated financial statements as of that date and were
                retroactively adjusted, including shares and per share amounts,
                as a result of the Reorganization. See the BridgeBio Pharma,
                Inc. Registration Statement on Form S-1 (File No. 333-231759)
                for additional details.
              </p>

              <p>
                (2)     December 31, 2019 amount includes long-term marketable
                securities of $31.1 million.
              </p>

              <p><strong>About BridgeBio Pharma</strong></p>

              <p>
                BridgeBio is a team of experienced drug discoverers, developers
                and innovators working to create life-altering medicines that
                target well-characterized genetic diseases at their source.
                BridgeBio was founded in 2015 to identify and advance
                transformative medicines to treat patients who suffer from
                Mendelian diseases, which are diseases that arise from defects
                in a single gene, and cancers with clear genetic drivers.
                BridgeBio’s pipeline of over 20 development programs includes
                product candidates ranging from early discovery to late-stage
                development. For more information, visit <a
                  href="https://www.globenewswire.com/Tracker?data=-yyNeu5xfoeu9sIJJJWB-p1F2uVpgpU_iZhLjMhP5sMfvyd0kcm89TvlmYigmW9LlqkWVXjnea0gqSWmknyQBg=="
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                >.
              </p>

              <p>
                <strong>BridgeBio Pharma Forward-Looking Statements</strong>
              </p>

              <p>
                This press release contains forward-looking statements.
                Statements we make in this press release may include statements
                that are not historical facts and are considered forward-looking
                within the meaning of Section 27A of the Securities Act of 1933,
                as amended (the “Securities Act”), and Section 21E of the
                Securities Exchange Act of 1934, as amended (the “Exchange
                Act”), which are usually identified by the use of words such as
                “anticipates,” “believes,” “estimates,” “expects,” “intends,”
                “may,” “plans,” “projects,” “seeks,” “should,” “will,” and
                variations of such words or similar expressions.  We intend
                these forward-looking statements to be covered by the safe
                harbor provisions for forward-looking statements contained in
                Section 27A of the Securities Act and Section 21E of the
                Exchange Act and are making this statement for purposes of
                complying with those safe harbor provisions. These
                forward-looking statements, including statements relating to
                expectations, plans and prospects regarding the preclinical and
                clinical development plans, clinical trial designs, clinical and
                therapeutic potential, and strategy of BridgeBio’s product
                candidates, including, but not limited to, the number of
                potential medicines in our portfolio, our plans to file an NDA
                for infigratinib in cholangiocarcinoma and multiple INDs for new
                product candidates in 2020, the initiation of our planned Phase
                2/3 trial of Zuretinol, the availability of topline data from
                our Phase 1/2 study of BBP-589, the anticipated dosing of the
                first child in our Phase 2 dose-ranging study of infigratinib in
                achondroplasia, the completion of enrollment in our ongoing
                Phase 3 study of BBP-265 in ATTR-CM and the commencement of our
                planned Phase 3 study of BBP-265 in ATTR-PN, the availability of
                updated results for infigratinib and our plans for further
                clinical development of infigratinib in FGFR+ cancer, and the
                timing of these events, reflect our current views about our
                plans, intentions, expectations, strategies and prospects, which
                are based on the information currently available to us and on
                assumptions we have made. Although we believe that our plans,
                intentions, expectations, strategies and prospects as reflected
                in or suggested by those forward-looking statements are
                reasonable, we can give no assurance that the plans, intentions,
                expectations or strategies will be attained or achieved. 
                Furthermore, actual results may differ materially from those
                described in the forward-looking statements and will be affected
                by  a number of risks, uncertainties and assumptions, including,
                but not limited to, those risks set forth in the Risk Factors
                section of our most recent quarterly or annual periodic report
                filed with the SEC and our other SEC filings. Moreover,
                BridgeBio operates in a very competitive and rapidly changing
                environment in which new risks emerge from time to time. These
                forward-looking statements are based upon the current
                expectations and beliefs of BridgeBio’s management as of the
                date of this release, and are subject to certain risks and
                uncertainties that could cause actual results to differ
                materially from those described in the forward-looking
                statements. Except as required by applicable law, we assume no
                obligation to update publicly any forward-looking statements,
                whether as a result of new information, future events or
                otherwise.
              </p>

              <p>
                <strong>Media Contact:</strong><br />Grace Rauh, BridgeBio
                Pharma<br /><a
                  href="https://www.globenewswire.com/Tracker?data=csZBecb3aLEhABUHDH4vmCWC_5fFKK2wMhxypbDCFDzDsZeJZlfFyAKEghe5J8rZXxcW6b5WlxJ0LPnN2leiKf-hty3lNabCNd6DIrKTLgM="
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="cfa8bdaeacaae1bdaebaa78fadbda6aba8aaada6a0abaab9e1b8bfaaa1a8a6a1aae1aca0a2"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                ><br />917-232-5478
              </p>

              <p>
                <strong>Investor Contact:</strong><br />John Grimaldi, Burns
                McClellan<br /><a
                  href="https://www.globenewswire.com/Tracker?data=GGnwfKcjZecCMCAa5_eHk6ilUOKe9ViTI3Pm2eWtMnBXuG95C2JBw1taN3rVde9kXazkxQVEaTbozbfGpRlgj6OT1_dMjMu9oGMwRd3sv_M="
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="036964716a6e626f676a436176716d706e602d606c6e"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                ><br />212-213-0006 x362
              </p>

              <p>Source: BridgeBio Pharma</p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4>
              <a href="../archive/index.html" class="red uppercase"
                >News Archive</a
              >
            </h4>
            <small class="date">03.02.2020</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#137a7d757c5371617a777476717a7c3d707c7e"
              ><span
                class="__cf_email__"
                data-cfemail="157c7b737a5577677c717270777c7a3b767a78"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
